133 related articles for article (PubMed ID: 35770280)
21. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
[TBL] [Abstract][Full Text] [Related]
22. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
Klement RJ; Abbasi-Senger N; Adebahr S; Alheid H; Allgaeuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Eble MJ; Ernst I; Gerum S; Habermehl D; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lewitzki V; Lohaus F; Ostheimer C; Papachristofilou A; Petersen C; Rieber J; Schneider T; Schrade E; Semrau R; Wachter S; Wittig A; Guckenberger M; Andratschke N
BMC Cancer; 2019 Feb; 19(1):173. PubMed ID: 30808323
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control.
Patel PR; Kirkpatrick J; Salama JK; Nelson J; Broadwater G; Allen K; Clough R; Yin FF; Wang Z; Chang Z; Kelsey C; Ghafoori AP
J Radiosurg SBRT; 2014; 3(2):123-129. PubMed ID: 29296393
[TBL] [Abstract][Full Text] [Related]
25. Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy.
Binkley MS; Trakul N; Jacobs LR; von Eyben R; Le QT; Maxim PG; Loo BW; Shultz DB; Diehn M
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1044-1052. PubMed ID: 26025776
[TBL] [Abstract][Full Text] [Related]
26. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors.
Clerici E; Comito T; Franzese C; Di Brina L; Tozzi A; Iftode C; Navarria P; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Apr; 196(4):325-333. PubMed ID: 31605163
[TBL] [Abstract][Full Text] [Related]
27. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease.
Rosenbrock J; Lieser A; Ostermann-Myrau J; Judge M; Linde P; Claus K; Marnitz S; Kocher M; Baues C; Celik E
Anticancer Res; 2023 Sep; 43(9):4125-4131. PubMed ID: 37648304
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer.
Chang JY; Liu YH; Zhu Z; Welsh JW; Gomez DR; Komaki R; Roth JA; Swisher SG
Cancer; 2013 Sep; 119(18):3402-10. PubMed ID: 23798353
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
32. Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience.
Singh R; Konrad A; Roubil JG; Jenkins J; Davis J; Austin Vargo J; Gogineni E; Sharma S
Radiother Oncol; 2024 Jan; 190():110020. PubMed ID: 38007042
[TBL] [Abstract][Full Text] [Related]
33. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
34. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
[TBL] [Abstract][Full Text] [Related]
35. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases.
Sole CV; Lopez Guerra JL; Matute R; Jaen J; Puebla F; Rivin E; Sanchez-Reyes A; Beltran C; Bourgier C; Calvo FA; Marsiglia H
Clin Transl Oncol; 2013 Jun; 15(6):484-91. PubMed ID: 23143953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
